Skip to main content

March 2010 - FRMC

Department

News Connection
03/18/2010
A study published in the Journal of the American Medical Association has reported a decline in biomedical research funding from 2003 to 2008, after a decade of doubling in funding growth.
A study published in the Journal of the American Medical Association has reported a decline in biomedical research funding from 2003 to 2008, after a decade of doubling in funding growth.
A study published in the Journal...
03/18/2010
First Report Managed Care
Conference Insider
03/18/2010
Utilizing patient-centered medical homes and increasing the use of health information technology may help the healthcare industry battle growing healthcare costs while providing high-quality care. 
Utilizing patient-centered medical homes and increasing the use of health information technology may help the healthcare industry battle growing healthcare costs while providing high-quality care. 
Utilizing patient-centered...
03/18/2010
First Report Managed Care
News Connection
03/18/2010
With the health reform battle grinding on, premium increases in California and other states have been held up by legislators as the latest evidence that insurers need to be reigned in. 
With the health reform battle grinding on, premium increases in California and other states have been held up by legislators as the latest evidence that insurers need to be reigned in. 
With the health reform battle...
03/18/2010
First Report Managed Care
News Connection
03/18/2010
Comprehensive legislation has been the centerpiece of the healthcare debate, but substantial portions of the reform agenda were enacted months before President Obama began calling for a final vote.
Comprehensive legislation has been the centerpiece of the healthcare debate, but substantial portions of the reform agenda were enacted months before President Obama began calling for a final vote.
Comprehensive legislation has...
03/18/2010
First Report Managed Care
Department
03/18/2010
Ampyra (dalfampridine) is a potassium channel blocker taken orally as a treatment to improve walking in patients with multiple sclerosis. 
Ampyra (dalfampridine) is a potassium channel blocker taken orally as a treatment to improve walking in patients with multiple sclerosis. 
Ampyra (dalfampridine) is a...
03/18/2010
First Report Managed Care
Feature
03/18/2010
Results from a randomized, controlled, clinical trial show that primary care practices can initiate effective medical management programs to treat extremely obese patients but maintaining weight loss remains difficult and needs further...
Results from a randomized, controlled, clinical trial show that primary care practices can initiate effective medical management programs to treat extremely obese patients but maintaining weight loss remains difficult and needs further...
Results from a randomized,...
03/18/2010
First Report Managed Care